
Sanofi SNY
$ 46.73
-1.83%
Annual report 2025
added 04-04-2026
Sanofi DSO Ratio 2011-2026 | SNY
Annual DSO Ratio Sanofi
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | 95.2 | 92.7 | 96.4 | 97 | 97.5 | 83.7 |
All numbers in EUR currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 97.5 | 83.7 | 93.8 |
DSO Ratio of other stocks in the Biotechnology industry
| Issuer | DSO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Autolus Therapeutics plc
AUTL
|
58.2 | $ 1.35 | -2.91 % | $ 359 M | ||
|
Coherus BioSciences
CHRS
|
559 | $ 1.61 | -3.59 % | $ 189 M | ||
|
I-Mab
IMAB
|
271 | - | - | $ 866 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
84.7 | - | - | $ 40.3 B | ||
|
Catalyst Pharmaceuticals
CPRX
|
59.5 | $ 24.88 | -0.4 % | $ 3.04 B | ||
|
Corbus Pharmaceuticals Holdings
CRBP
|
239 | $ 10.02 | -1.16 % | $ 133 M | ||
|
Midatech Pharma plc
MTP
|
204 | - | -18.52 % | $ 27.3 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
2.75 K | - | -1.52 % | $ 24.7 M | ||
|
Cardiff Oncology
CRDF
|
294 | $ 1.57 | -0.63 % | $ 105 M | ||
|
Acorda Therapeutics
ACOR
|
48.3 | - | -24.86 % | $ 820 K | ||
|
Alterity Therapeutics Limited
ATHE
|
16.2 K | $ 3.65 | 1.3 % | $ 8.78 B | ||
|
Advaxis
ADXS
|
88.1 | - | -9.65 % | $ 45.9 M | ||
|
DBV Technologies S.A.
DBVT
|
71.3 | $ 20.25 | -0.54 % | $ 2.83 B | ||
|
Adverum Biotechnologies
ADVM
|
222 | - | - | $ 86.2 M | ||
|
Aytu BioScience
AYTU
|
150 | $ 2.55 | -4.14 % | $ 16 M | ||
|
Dyadic International
DYAI
|
78.4 | $ 0.87 | - | $ 31.5 M | ||
|
Aeterna Zentaris
AEZS
|
146 | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
186 | - | -10.17 % | $ 12.2 K | ||
|
Aeglea BioTherapeutics
AGLE
|
216 | - | - | $ 1.01 B | ||
|
Equillium
EQ
|
16.6 | $ 2.0 | -0.5 % | $ 115 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
0.114 | - | - | $ 26.5 M | ||
|
Evogene Ltd.
EVGN
|
30 | $ 0.8 | 2.49 % | $ 27.9 M | ||
|
AIkido Pharma
AIKI
|
17.9 | - | 1.93 % | $ 17.4 M | ||
|
Fate Therapeutics
FATE
|
122 | $ 1.15 | -3.78 % | $ 137 M | ||
|
Fennec Pharmaceuticals
FENC
|
148 | $ 6.2 | -3.43 % | $ 177 M | ||
|
Amicus Therapeutics
FOLD
|
62.3 | $ 14.46 | 0.03 % | $ 4.46 B | ||
|
CureVac N.V.
CVAC
|
13.6 | - | - | $ 867 M | ||
|
Fulcrum Therapeutics
FULC
|
6.75 | $ 7.45 | -4.85 % | $ 472 K | ||
|
Alnylam Pharmaceuticals
ALNY
|
58.1 | $ 315.4 | -4.52 % | $ 41.3 B | ||
|
Alpine Immune Sciences
ALPN
|
154 | - | - | $ 2.17 B | ||
|
Gilead Sciences
GILD
|
57.8 | $ 138.37 | -1.26 % | $ 172 B | ||
|
Galmed Pharmaceuticals Ltd.
GLMD
|
33.4 | $ 0.54 | 4.26 % | $ 503 K | ||
|
Genmab A/S
GMAB
|
97.9 | $ 27.13 | -2.25 % | $ 17 B |